查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950439

CDK4/6抑制劑市場按應用、藥物類別、劑型、通路和最終用戶分類，全球預測，2026-2032年

CDK4/6 Inhibitors Market by Indication, Drug Class, Formulation, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

CDK4/6 抑制劑市場預計到 2025 年將達到 142.5 億美元，到 2026 年將成長到 158 億美元，到 2032 年將達到 284.5 億美元，複合年成長率為 10.38%。

關鍵市場統計數據
基準年 2025 142.5億美元
預計年份：2026年 158億美元
預測年份 2032 284.5億美元
複合年成長率 (%) 10.38%

探討 CDK4/6 抑制劑在腫瘤學領域的策略崛起，及其對現代治療路徑的臨床、監管和相關人員的影響

CDK4/6抑制劑的臨床應用已從早期概念驗證階段發展成為荷爾蒙驅動型乳癌治療的核心支柱，這促使治療流程、支付方策略和臨床路徑進行調整。近年來累積的臨床證據表明，該類藥物在特定患者群體中具有持久療效，並強調了精準的患者篩選、毒性管理和治療順序策略的重要性。因此，臨床、商業和政策相關人員在重新評估這些治療方法如何與內分泌治療、標靶治療以及不斷發展的生物標記框架相結合。

識別重塑 CDK4/6 抑制劑應用格局的變革性變化，包括新的試驗數據、聯合用藥策略、監管創新和支付方趨勢。

多種變革性因素正在重塑 CDK4/6 抑制劑領域，每一種因素都對臨床實踐和商業化產生影響。高品質的臨床試驗數據和不斷擴展的真實世界證據正在完善這些藥物的臨床特徵，促使臨床醫生採用更個人化的治療順序和聯合治療策略，優先考慮長期疾病控制並兼顧耐受性。同時，能夠加速核准和擴展適應症的監管途徑也在不斷發展，這些途徑反映了基於​​生物標記的亞組資訊，從而影響著藥物上市討論和與支付方的談判。

評估美國2025年實施的關稅對CDK4/6抑制劑供應鏈、採購成本和全球取得途徑的累積影響

2025年美國關稅政策的實施，為全球CDK4/6抑制劑的供應和採購環境引入了新的變數，促使相關人員重新評估其採購和分銷安排。供應鏈經理和採購團隊面臨越來越大的壓力，他們需要應對諸如供應商多元化、審查庫存政策以及評估關鍵生產營運的地理位置等挑戰。這些決策受到前置作業時間、跨司法管轄區的監管合規性以及確保患者持續獲得口服抗癌藥物等關鍵因素的影響。

按適應症、藥物類別、通路、最終用戶和劑型提取可操作的細分洞察，以指導商業規劃。

嚴謹的細分分析闡明了 CDK4/6 抑制劑的臨床需求、商業性機會和營運複雜性之間的交集。適應症細分將荷爾蒙受體陽性、HER2 陰性乳癌和男性乳癌識別為不同的臨床隊列，其中前者進一步細分為早期和轉移性治療，需要不同的臨床方法和實證依據。藥物類別細分根據安全性、給藥方案和臨床定位區分了阿貝西利、Palbociclib和瑞博西尼，這些因素影響處方趨勢和支持服務需求。

檢驗美洲、歐洲、中東和非洲以及亞太地區的區域因素將如何影響 CDK4/6 療法的可近性、報銷方式和臨床應用。

區域趨勢將對 CDK4/6 療法的取得、報銷和整合到臨床路徑中的方式產生深遠影響。在美洲，醫療保健系統多種多樣，從高度標準化的公共項目到複雜的多方付費環境，都要求申辦方透過有針對性的證據和定價策略，探索廣泛的報銷和獲取途徑。在歐洲、中東和非洲，法規環境和支付環境不均衡，各國決策、區域採購慣例和癌症治療基礎設施的差異，要求制定本地化的市場進入策略和實施計劃。在亞太地區，一些都市區的臨床應用進展迅速，而其他地區則面臨基礎設施和經濟方面的障礙，因此需要可擴展的患者支持模式和夥伴關係，以擴展診斷能力和依從性支持。

評估領先的 CDK4/6 開發商的競爭定位、產品線差異化、製造策略和商業性策略，以指南夥伴關係的發展。

活躍於 CDK4/6 領域的公司在臨床開發、生產規模和市場定位方面展現出不同的策略，影響競爭動態。一些公司專注於差異化的臨床項目和適應症拓展，透過投資頭對頭研究和聯合用藥研究，打造引人入勝的臨床案例。另一些公司則專注於提高生產效率和增強供應鏈的穩健性，以支援穩定的產品供應和全球分銷。商業策略涵蓋了從完善的患者支持體系和數位化藥物管理工具，到與腫瘤科醫生和支付方的深度合作，以將臨床試驗結果轉化為本地臨床實踐等各個方面。

為產業領導者提供臨床合作、供應彈性、證據產生和商業模式的實用建議，以最佳化 CDK4/6 抑制劑的推廣應用

產業領導者應優先考慮一系列切實可行的措施，以共同增強 CDK4/6 領域的臨床影響力和商業性韌性。首先，產生與真實臨床問題相符的證據，例如治療順序、長期耐受性和亞組療效，將增強臨床醫生的信心和支付方的認可。其次，投資供應鏈多元化和透明的庫存策略將降低貿易中斷帶來的風險，並確保患者治療的連續性。

明確調查方法、資料收集方法、專家檢驗和分析框架，以支持對 CDK4/6 動態的可靠認知

本報告的研究結合了結構化的原始研究和二手研究，以確保分析的嚴謹性和實際應用價值。原始研究包括對腫瘤科醫生、藥屋主任、支付方和供應鏈高管的專家訪談，以收集從業人員對臨床應用、分銷挑戰和報銷趨勢的觀點。二手研究整合了同儕審查文獻、監管文件和公共資料，建構了一個全面的證據基礎，以補充從業人員的見解。

CDK4/6抑制劑臨床進展、進入挑戰、競爭動態和未來發展重點策略要點

綜合研究結果凸顯了幾個長期存在的主題：臨床差異化驅動處方行為，藥物可及性依賴於支付方的協作參與和可操作證據的生成，而運營韌性則保障了患者獲得可靠醫療服務。臨床數據和聯合治療策略的進步有望改善治療效果，但也帶來了更複雜的治療決策，並促使支付方對更完善的證據提出更高的要求。同時，從關稅到配藥方式等供應鏈和分銷因素，都是影響價格談判和業務連續性的策略變數。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. CDK4/6抑制劑市場（依適應症分類）

  • 荷爾蒙受體陽性、HER2陰性乳癌
    • 早期
    • 轉移性
  • 男性乳癌

9. CDK4/6抑制劑市場依藥物類別分類

  • 阿貝西利
  • Palbociclib
  • 利博西克利

第10章：CDK4/6抑制劑市場（依劑型分類）

  • 膠囊
  • 口服錠劑

第11章：CDK4/6抑制劑市場（依分銷管道分類）

  • 電子商務
  • 醫院藥房
    • 住院病人
    • 郵購
  • 零售藥房

第12章：CDK4/6抑制劑市場（依最終用戶分類）

  • 醫院
  • 腫瘤中心
  • 專科診所

13. CDK4/6抑制劑市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 CDK4/6抑制劑市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. CDK4/6抑制劑市場（按國家分類）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國 CDK4/6 抑制劑市場

17. 中國 CDK4/6 抑制劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Astex Pharmaceuticals
  • AstraZeneca plc
  • Bayer AG
  • Beida Pharmaceutical Company
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • G1 Therapeutics
  • Hanmi Pharm
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Nuvation Bio
  • Onconova Therapeutics Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Shanghai Pharmaceutical Group
Product Code: MRR-4F7A6D4FD865

The CDK4/6 Inhibitors Market was valued at USD 14.25 billion in 2025 and is projected to grow to USD 15.80 billion in 2026, with a CAGR of 10.38%, reaching USD 28.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.25 billion
Estimated Year [2026] USD 15.80 billion
Forecast Year [2032] USD 28.45 billion
CAGR (%) 10.38%

Framing the strategic emergence of CDK4/6 inhibitors in oncology with clinical, regulatory, and stakeholder implications for contemporary treatment pathways

The clinical landscape for CDK4/6 inhibitors has matured from early proof-of-concept into a central pillar of hormone-driven breast cancer management, prompting a recalibration of treatment algorithms, payer approaches, and clinical pathways. Recent years have seen accumulated clinical evidence that underscores durable benefit in selected patient populations and has elevated the importance of nuanced patient selection, toxicity management, and sequencing strategies. As a result, stakeholders across clinical, commercial, and policy domains are reassessing how these therapies integrate with endocrine agents, targeted treatments, and evolving biomarker frameworks.

This introductory overview situates CDK4/6 inhibitors within the broader oncology ecosystem by highlighting critical inflection points that matter to decision-makers. Real-world adoption depends not only on efficacy and safety profiles but on operational elements such as prescribing patterns, monitoring infrastructure, and patient support programs. Consequently, the interplay between clinical evidence, health system readiness, and commercial execution will determine the short- and medium-term practical impact of CDK4/6 agents in routine care.

Identifying transformative shifts reshaping CDK4/6 inhibitor adoption including emerging trial data, combination strategies, regulatory innovations and payer shifts

Several transformative forces are reshaping the CDK4/6 inhibitor landscape, each carrying implications for clinical practice and commercialization. High-quality trial data and expanding real-world evidence have refined the clinical profile of these agents, leading clinicians to adopt more tailored sequencing and combination strategies that prioritize long-term disease control while managing tolerability. At the same time, regulatory pathways have evolved to accommodate accelerated approvals and label expansions informed by biomarker-driven subgroups, which in turn influence formulary discussions and payer negotiations.

Parallel to clinical and regulatory shifts, innovation in combination regimens-pairing CDK4/6 inhibitors with endocrine therapies, targeted agents, or novel modalities-has opened new therapeutic possibilities while introducing complexity to treatment algorithms. Payer landscapes are responding by demanding more robust health economics and outcomes evidence to justify coverage and reimbursement. Operationally, manufacturers and health systems are adapting through expanded patient support programs, digital adherence tools, and streamlined diagnostic workflows to address the practical barriers to sustained therapy. Taken together, these dynamics are converging to redefine standard-of-care choices and to create differentiation opportunities for sponsors that can demonstrate clear value propositions across clinical and economic dimensions.

Assessing cumulative consequences of United States tariff measures in 2025 on CDK4/6 inhibitor supply chains, procurement costs, and global access pathways

The introduction of tariff measures in the United States during 2025 introduced new variables into the global CDK4/6 supply and procurement environment, prompting stakeholders to reassess sourcing and distribution arrangements. Supply chain managers and procurement teams faced elevated pressure to diversify suppliers, revisit inventory policies, and evaluate the geographic footprint of key manufacturing steps. These decisions were influenced by lead-time considerations, regulatory compliance across jurisdictions, and the critical need to maintain uninterrupted patient access to oral oncology agents.

Beyond immediate logistics, the tariff environment prompted downstream effects on contracting and pricing negotiations with distributors, hospital systems, and specialty pharmacies. Manufacturers and distributors increasingly prioritized supply resilience and transparency, investing in alternative supply routes and near-shoring where feasible to mitigate exposure. From a clinical access perspective, health systems and oncology centers had to balance budgetary constraints with continuity of care, reinforcing the role of patient assistance programs and collaborative planning between manufacturers and payers. In summary, tariff-driven disruptions underscored the interconnectedness of global manufacturing, regulatory compliance, and patient access strategies, making supply chain agility a strategic imperative.

Distilling actionable segmentation insights across indication, drug class, distribution channel, end user, and formulation to inform commercial planning

A rigorous segmentation lens clarifies where clinical need, commercial opportunity, and operational complexity intersect for CDK4/6 inhibitors. Indication segmentation recognizes hormone receptor positive HER2 negative breast cancer and male breast cancer as distinct clinical cohorts, with the former further differentiated into early stage and metastatic treatment contexts that necessitate varied clinical approaches and evidence bases. Drug class segmentation differentiates Abemaciclib, Palbociclib, and Ribociclib by their individual safety profiles, dosing paradigms, and clinical positioning, which in turn shape prescribing preferences and support service requirements.

Distribution channel considerations span e-commerce, hospital pharmacies, and retail pharmacies, with hospital pharmacies themselves encompassing inpatient and mail order modalities that affect dispensing logistics and adherence supports. End user segmentation highlights the differing operational realities and decision drivers at hospitals, oncology centers, and specialty clinics, where formulary processes, oncology nurse roles, and infusion-adjacent services influence uptake and long-term management. Finally, formulation differentiation between capsules and oral tablets affects packaging, adherence, and patient counseling needs. Taken together, these segmentation dimensions point to targeted strategies: evidence generation tailored to indication and stage, differentiation based on drug-specific clinical characteristics, distribution models optimized for patient access and adherence, and end-user engagement calibrated to institutional workflows and treatment delivery models.

Examining how regional forces in the Americas, EMEA, and Asia-Pacific influence CDK4/6 therapeutic access, reimbursement approaches, and clinical uptake

Regional dynamics exert a profound influence on how CDK4/6 therapies are accessed, reimbursed, and integrated into clinical pathways. In the Americas, health systems vary from highly standardized public programs to complex multi-payer environments, creating a spectrum of reimbursement and access mechanisms that sponsors must navigate through targeted evidence and pricing strategies. Europe, Middle East & Africa present heterogeneous regulatory and payer environments where national decision-making, regional procurement practices, and differing levels of oncology infrastructure require locally adapted market access and launch plans. Asia-Pacific markets display rapid clinical uptake in certain urban centers while facing infrastructure and affordability barriers in other areas, driving a need for scalable patient support models and partnerships that extend diagnostic and adherence capabilities.

Across these regions, differences in diagnostic availability, clinician familiarity with CDK4/6 agents, and the maturity of oral oncology programs shape adoption curves. Reimbursement criteria and health technology assessment approaches also vary markedly, necessitating region-specific health economics evidence and real-world data strategies. Ultimately, successful engagement requires a nuanced appreciation of regional payer frameworks, clinical practice norms, and operational constraints, combined with strategic investments in local evidence generation and provider education to support sustainable uptake.

Evaluating competitive positioning, pipeline differentiation, manufacturing strategies, and commercial tactics among leading CDK4/6 developers to guide partnerships

Companies active in the CDK4/6 space exhibit distinct approaches to clinical development, manufacturing scale, and market positioning that influence competitive dynamics. Some developers emphasize differentiated clinical programs and label expansions, investing in head-to-head or combination studies to create a compelling clinical narrative. Others focus on manufacturing efficiencies and supply chain robustness to ensure consistent product availability and to support global distribution. Commercial tactics range from strong patient support infrastructures and digital adherence tools to deep engagements with oncology clinicians and payers that translate trial outcomes into local practice.

Strategic partnerships and licensing arrangements also play a central role in shaping company trajectories, enabling access to regional distribution networks, diagnostic platforms, and localized expertise. Corporate strategies that align clinical differentiation with operational excellence and proactive payer engagement tend to create stronger positioning, particularly as health systems demand clear evidence of value and predictable supply. For stakeholders evaluating competitive landscapes, it is essential to assess pipeline focus areas, manufacturing resilience, and the depth of commercial and clinical support services that underpin sustained adoption.

Actionable recommendations for industry leaders on clinical engagement, supply resilience, evidence generation, and commercial models to optimize CDK4/6 uptake

Industry leaders should prioritize a set of actionable moves that collectively strengthen clinical impact and commercial resilience in the CDK4/6 domain. First, aligning evidence generation with real-world clinical questions-such as sequencing, long-term tolerability, and subgroup effectiveness-will deepen clinician confidence and payer acceptance. Second, investing in supply chain diversification and transparent inventory strategies will reduce vulnerability to trade disruptions and ensure continuity of treatment for patients.

Third, designing patient-centric support programs that address adherence, toxicity management, and financial navigation will enhance treatment persistence and clinical outcomes. Fourth, proactive payer engagement founded on robust health outcomes evidence and practical cost-of-care frameworks will facilitate reimbursement conversations. Finally, forging collaborative partnerships across diagnostic providers, specialty pharmacies, and clinical networks can accelerate adoption while mitigating operational hurdles. Executing these recommendations with clear timelines and measurable objectives will enable organizations to convert insight into material improvements in patient access and therapeutic value.

Clarifying research methodology, data collection approaches, expert validation, and analytical frameworks that underpin reliable insights on CDK4/6 dynamics

The research underpinning this report integrates structured primary and secondary approaches designed to ensure analytical rigor and practical relevance. Primary research comprised expert interviews with oncologists, pharmacy directors, payers, and supply chain executives to capture practitioner perspectives on clinical use, distribution challenges, and reimbursement dynamics. Secondary research synthesized peer-reviewed literature, regulatory documentation, and public policy sources to construct a comprehensive evidence base that complements practitioner insights.

Analytical frameworks applied in the study include comparative clinical profile assessments, supply chain vulnerability mapping, and stakeholder impact analyses that consider regulatory and payer heterogeneity. Expert validation rounds were conducted to test emerging findings and to refine interpretations. This mixed-methods approach yields balanced, actionable insights by combining quantitative literature-based evidence with qualitative insights from frontline stakeholders, thereby supporting robust conclusions about clinical, operational, and commercial implications for CDK4/6 therapies.

Summarizing strategic takeaways on clinical progress, access challenges, competitive dynamics, and the priorities that will shape the future trajectory of CDK4/6

The consolidated findings emphasize a few persistent themes: clinical differentiation drives prescribing behavior; access depends on coordinated payer engagement and pragmatic evidence generation; and operational resilience underpins reliable patient access. Advances in clinical data and combination strategies have raised expectations for improved outcomes, but they have also increased complexity in treatment decision-making and in the evidence required by payers. Concurrently, supply chain and distribution considerations-from tariffs to dispensing modalities-have become strategic variables that influence both price negotiations and operational continuity.

Looking ahead, stakeholders that integrate robust clinical strategies with resilient supply models, targeted regional approaches, and sophisticated payer engagement will be best positioned to realize the therapeutic and commercial potential of CDK4/6 agents. The priorities that emerge from this synthesis provide a practical roadmap for sponsors, providers, and payers seeking to optimize patient outcomes while navigating an increasingly complex therapeutic environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CDK4/6 Inhibitors Market, by Indication

  • 8.1. Hormone Receptor Positive HER2 Negative Breast Cancer
    • 8.1.1. Early Stage
    • 8.1.2. Metastatic
  • 8.2. Male Breast Cancer

9. CDK4/6 Inhibitors Market, by Drug Class

  • 9.1. Abemaciclib
  • 9.2. Palbociclib
  • 9.3. Ribociclib

10. CDK4/6 Inhibitors Market, by Formulation

  • 10.1. Capsules
  • 10.2. Oral Tablets

11. CDK4/6 Inhibitors Market, by Distribution Channel

  • 11.1. E Commerce
  • 11.2. Hospital Pharmacies
    • 11.2.1. Inpatient
    • 11.2.2. Mail Order
  • 11.3. Retail Pharmacies

12. CDK4/6 Inhibitors Market, by End User

  • 12.1. Hospitals
  • 12.2. Oncology Centers
  • 12.3. Specialty Clinics

13. CDK4/6 Inhibitors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. CDK4/6 Inhibitors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. CDK4/6 Inhibitors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States CDK4/6 Inhibitors Market

17. China CDK4/6 Inhibitors Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Astex Pharmaceuticals
  • 18.7. AstraZeneca plc
  • 18.8. Bayer AG
  • 18.9. Beida Pharmaceutical Company
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Eli Lilly and Company
  • 18.12. G1 Therapeutics
  • 18.13. Hanmi Pharm
  • 18.14. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 18.15. Merck & Co., Inc.
  • 18.16. Novartis AG
  • 18.17. Nuvation Bio
  • 18.18. Onconova Therapeutics Inc.
  • 18.19. Pfizer Inc.
  • 18.20. Roche Holding AG
  • 18.21. Sanofi S.A.
  • 18.22. Shanghai Pharmaceutical Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CDK4/6 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CDK4/6 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CDK4/6 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY METASTATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY METASTATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY METASTATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY MALE BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY MALE BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY MALE BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ABEMACICLIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ABEMACICLIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ABEMACICLIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY PALBOCICLIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY PALBOCICLIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY PALBOCICLIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY RIBOCICLIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY RIBOCICLIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY RIBOCICLIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY E COMMERCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY E COMMERCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY E COMMERCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY MAIL ORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY MAIL ORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY MAIL ORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GCC CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. GCC CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 141. GCC CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. G7 CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. G7 CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 161. G7 CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. G7 CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 165. G7 CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. NATO CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. NATO CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. NATO CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. NATO CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 173. NATO CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA CDK4/6 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)